SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Somatropin For Injection (Single Dose Syringe: 0.6mg - 2.0mg)

Trade Name: Genotropin Miniquick®; Genotonorm Miniquick; Genotropin MQ
Synonyms: Human Growth Hormone; HGH; Somatotropin
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product for the treatment of human growth hormone deficiency

Details of the Supplier of the Safety Data Sheet

ShunXin Fine Chemical CO., LIMITED
Phone : +8618230646395
WhatsApp: +8618230646395
Skype: kangcbio
Email: shunxinchem@yahoo.com
Emergency telephone number:
CHEMTREC (24 hours): +8618230646395

ShunXin Fine Chemical CO., LIMITED
huilongguan lianchuangkongjian 1023 BeiJing
China
+8618230646395
Emergency telephone number:
International CHEMTREC (24 hours):
+8618230646395

Contact E-Mail: shunxinchem@yahoo.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Acute Oral Toxicity: Category 4
Acute Dermal Toxicity: Category 4
Acute Toxicity - Dusts and Mists: Category 4
Skin Sensitization: Category 1
Reproductive Toxicity: Category 2

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

Label Elements

Signal Word: Warning
Hazard Statements:
H302 - Harmful if swallowed
H317 - May cause an allergic skin reaction
H361fd - Suspected of damaging fertility. Suspected of damaging the unborn child.
May form combustible dust concentrations in air
H312 - Harmful in contact with skin
H332 - Harmful if inhaled

Precautionary Statements:

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P271 - Use only outdoors or in a well-ventilated area
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P312 - Call a POISON CENTRE/doctor/physician if you feel unwell
P363 - Wash contaminated clothing before reuse
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Somatropin	12629-01-5	235-735-8	Acute Tox. 3 (H301) Acute Tox. 4 (H312, H332) Skin Sens. 1 (H317) Repr. 2 (H361fd)	30 - 59

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Glycine	56-40-6	200-272-2	Not Listed	*
Mannitol	69-65-8	200-711-8	Not Listed	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	Not Listed	*
Sodium phosphate, monobasic	7558-80-7	231-449-2	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: No data available

Fire / Explosion Hazards: Not available

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store as directed by product packaging.
Incompatible Materials:	None identified
Specific end use(s):	Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Somatropin

Pfizer OEL TWA-8 Hr:	10µg/m^3, Sensitizer

Glycine

Latvia OEL - TWA	5 mg/m^3

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Sodium phosphate, dibasic

Pfizer Occupational Exposure Band (OEB):	OEB 1 (control exposure to the range of 1000ug/m^3 to 3000ug/m^3)

Sodium phosphate, monobasic

Pfizer Occupational Exposure Band (OEB):	OEB 1 (control exposure to the range of 1000ug/m^3 to 3000ug/m^3)

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Lyophilized powder plus sterile diluent	**Color:**	White
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Water
No data available
Mannitol
No data available
Glycine
No data available
Sodium phosphate, dibasic
No data available
Sodium phosphate, monobasic
No data available
Somatropin
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: None identified
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Long Term: Animal studies indicate that this material may cause adverse effects on the blood, kidneys, liver, mammary gland.
Known Clinical Effects: Adverse effects associated with therapeutic use include glucose, intolerance, fluid retention, headache, and effects on the thyroid. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Drugs of this class may cause formation of antibodies

Acute Toxicity: (Species, Route, End Point, Dose)

Mannitol
Rat Oral LD 50 13500 mg/kg
Mouse Oral LD 50 22 g/kg

Glycine
Rat Oral LD 50 7930 mg/kg
Mouse Oral LD 50 4920mg/kg

Somatropin
Rat Oral LD50 242 mg/kg
Rat Dermal LD50 1100mg/kg
Rat Inhalation LC50 1h 710mg/m^3
Mouse Oral LD50 828mg/kg
Mouse Intraperitoneal LD50 828mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Somatropin
Skin Irritation Rabbit Negative
Not specified Guinea Pig Positive
Antigenicity- Active anaphylaxis Guinea Pig Positive
Antigenicity- Passive cutaneous anaphylaxis Guinea Pig Positive

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Somatropin
1 Month(s) Rat Intramuscular 0.63 mg/kg/day NOAEL Mammary gland

11. TOXICOLOGICAL INFORMATION

3 Month(s)	Rat	Subcutaneous	0.37 mg/kg/day	LOAEL	Liver, Adrenal gland, Kidney
3 Month(s)	Monkey	Subcutaneous	0.125 mg/kg/day	LOAEL	Mammary gland, Blood
52 Week(s)	Monkey	Subcutaneous	0.63 mg/kg/day	NOAEL	Adipose tissue, Mammary gland, Reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Somatropin

Embryo / Fetal Development	Rat	Subcutaneous	3.3 mg/kg/day	NOAEL	Not teratogenic
Embryo / Fetal Development	Rabbit	Intramuscular	0.3 mg/kg/day	NOAEL	Not Teratogenic
Embryo / Fetal Development	Rat	Subcutaneous	3.3 mg/kg/day	LOAEL	Fetotoxicity
Reproductive & Fertility	Rat	Subcutaneous	0.3 mg/kg/day	NOAEL	Fertility
Peri-/Postnatal Development	Rat	Subcutaneous	3.3 mg/kg/day	NOAEL	No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Somatropin

Bacterial Mutagenicity (Ames)	*Salmonella* , *E. coli*	Negative
In Vitro Mammalian Cell Mutagenicity	Mouse Lymphoma	Negative
In Vivo Chromosome Aberration	Rat Bone Marrow	Negative
In Vitro Chromosome Aberration	Human Lymphocytes	Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Somatropin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	235-735-8

Glycine

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-272-2

Mannitol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-711-8

Sodium phosphate, dibasic

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-448-7

Sodium phosphate, monobasic

CERCLA/SARA 313 Emission reporting	Not Listed

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-449-2

Water

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Acute toxicity, dermal-Cat.4; H312 - Harmful in contact with skin
Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction
Reproductive toxicity-Cat.2; H361fd - Suspected of damaging fertility. Suspected of damaging the unborn child.

Data Sources: Pfizer proprietary drug development information, Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 15-Mar-2018

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet